Vor Biopharma Quarterly Balance Sheet
NASDAQ: VORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vor Biopharma financial position
As of Jun 30, 2026, Vor Biopharma reported total assets of $481.1 million, up 134.2% from a year earlier against total liabilities of $681.3 million. Shareholders' equity was negative at -$200.2 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $107.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 19.15, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Vor Biopharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 107.86M | 169.87M | 396.49M | 160.46M | 190.57M | 50.05M | 81.95M | 52.80M | 76.08M | 44.96M | 31.36M | 45.03M |
| Short-Term Investments | 358.27M | 321.65M | 58.72M | 10.00M | 9.99M | 9.99M | 9.98M | 10.01M | 9.86M | 62.52M | 105.81M | 115.07M |
| Total Current Assets | 475.11M | 500.78M | 458.11M | 172.49M | 204.93M | 64.85M | 96.51M | 67.30M | 90.26M | 111.82M | 140.80M | 164.44M |
| Property, Plant & Equipment | 648.00K | 565.00K | 533.00K | 271.00K | 0 | 5.99M | 6.58M | 7.47M | 8.29M | 9.16M | 10.05M | 10.82M |
| Total Assets | 481.05M | 506.75M | 464.13M | 176.24M | 205.37M | 109.31M | 142.89M | 115.99M | 141.59M | 167.03M | 198.13M | 223.02M |
| Accounts Payable | 4.00M | 1.04M | 5.13M | 885.00K | 669.00K | 3.73M | 1.50M | 1.32M | 2.01M | 2.33M | 815.00K | 1.31M |
| Total Current Liabilities | 24.81M | 16.08M | 25.17M | 18.84M | 58.77M | 16.73M | 18.61M | 14.35M | 13.80M | 13.21M | 15.57M | 15.39M |
| Total Liabilities | 681.25M | 657.17M | 628.44M | 2.40B | 1.71B | 43.24M | 46.23M | 43.04M | 43.51M | 43.99M | 47.40M | 48.24M |
| Shareholders' Equity | -200.20M | -150.42M | -164.31M | -2.23B | -1.51B | 66.07M | 96.66M | 72.95M | 98.08M | 123.03M | 150.72M | 174.78M |
| Retained Earnings | -1.44B | -1.37B | -1.15B | -2.88B | -2.06B | -489.48M | -456.99M | -426.28M | -398.72M | -370.88M | -340.08M | -313.82M |
| Net Cash (Debt) | 466.13M | 491.52M | 455.21M | 170.46M | 200.56M | 60.03M | 91.93M | 62.81M | 85.94M | 107.48M | 137.18M | 160.10M |
| Shares Outstanding | 54.46M | 54.19M | 38.72M | 9.03M | 125.65M | 124.85M | 6.24M | 68.66M | 68.36M | 68.22M | 67.89M | 67.79M |
This table shows 12 quarterly periods of Vor Biopharma's balance sheet, from Q2 2026 back to Q3 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow VOR's reporting calendar. What is a balance sheet?